Hyperion Therapeutics Inc (NASDAQ:HPTX)
| 20.80 Data as of 4:00pm ET |  -0.84 / -3.88%Today’s Change | 9.95 Today|||52-Week Range 26.50 | +84.40% Year-to-Date |
Latest HPTX News | Press Releases
| 5 Stocks Rising on Unusual Volume May 20 / TheStreet.com |
Today’s Trading
| Previous close | 21.64 |
| Today’s open | 21.00 |
| Day’s range | 20.54 - 21.55 |
| Volume | 86,516 |
| Average volume (3 months) | 118,641 |
| Market cap | $433.7M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/21/2013
Growth & Valuation
| Earnings growth (last year) | -49.33% |
| Earnings growth (this year) | +86.46% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 10.48 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| PLXProtalix Biotherapeu... | +0.01 | +0.19% |
| OSIROsiris Therapeutics ... | +0.15 | +1.40% |
| CRISCuris Inc | -0.03 | -0.77% |
| NVAXNovavax Inc | -0.02 | -1.01% |
Data as of 4:03pm ET, 05/21/2013
Financials
| Next reporting date | September 6, 2013 |
| EPS forecast (this quarter) | -$0.11 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$32.3M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Donald J. Santel |
Chief Financial Officer & Secretary Jeffrey S. Farrow |
Corporate headquarters South San Francisco, California |
Forecasts
